Vycor: "On the Cusp of the Next Big Healthcare Trend"
NEW YORK, NY / ACCESSWIRE / November 10, 2014 / In the early 1980s researchers began to mimic cells of the immune system in creating monoclonal antibodies. Hugely successful products such as Infliximab by Johnson & Johnson (NYSE: JNJ) and Etanercept by Amgen (NASDAQ: AMGN) created a massive influx of prescient investors to the biotech sector. Further exploration with VEGF-inhibitors lead to the blockbuster Avastin by Roche with $6 billion in sales per year. Beginning in the late 1990's, research and development began to focus on personalized medicine which seeks to treat disorders with custom tailored treatments for each individual or subpopulations of individuals. Companies such as Medivation (NASDAQ: MDVN) and Puma Biotechnology (NYSE: PBYI) lead this field.
The therapeutic application of neuroplasticity is nascent but unequivocally the direction in which treatment of brain and nervous system disorders is moving at an alarming pace. Neuroplasticity is the ability of individual or groups of neurons to functionally reorganize, in many cases, as a compensatory mechanism to recover lost function due to traumatic brain injury or stroke.
It is the responsibility of a good analyst to identify what will be the next trend so as to be the first in the space and the next trend is the therapeutic utilization of neuroplasticity. To this extent, Vycor Medical (OTCQB: VYCO) is where to look.
One Equity Research will be initiating coverage of Vycor Medical (VYCO), which we believe trades at a compelling valuation in the marketplace when compared to medical device peers such as Abiomed (NASDAQ: ABMD), Accuray (NASDAQ: ARAY), Hologic (NASDAQ: HOLX) and particularly when compared to diagnostic companies such as Organovo (NYSE MKT: ONVO) and Exact Sciences (NASDAQ: EXAS).
In our initiation report, we will further explore:
·Neurons and how they learn
·How Vycor is using neuroplasticity to reach unmet needs
·Market opportunity
·What's driving Vycor's compounded 5-yr sales growth of 45.55%
·Risk profile
·Fair value and valuation models to assess asymmetrical upside investment opportunity
Subscribe here to receive an alert when our full initiation report becomes available.
About the Analyst
Dante Ruffalo is a former biomedical research scientist published in Neuroscience and Psychophysiology. Mr. Ruffalo is also a patent attorney, an economic advisor and a research fellow at a Eurasian think tank where he collaborates with European counter parties in writing white papers that seek to advance science curricula. Mr. Ruffalo is a member of the high IQ society Mensa and writes Mensa's economics column for their monthly publication.
About One Equity Research
One Equity Research is a leading provider of proprietary and in-depth research crafted by respected financial analysts and domain experts. Our team includes trained finance professionals with diverse backgrounds that include equity research, investment banking, and strategic consulting at preeminent firms. We distribute our research through mainstream media partners and to subscribers of our Intelligence Service.
Legal Disclaimer
The report described in this press release has been prepared by One Equity Research, LLC on behalf of Vycor Medical, Inc. (the "Company"), as part of investor relations services provided to Vycor Medical by One Equity Research. One Equity Research has been compensated ten thousand dollars per month for a period of up to four months for ongoing research coverage as fully disclosed on One Equity Research. Dante Ruffalo is the author of the report and the views regarding Vycor Medical expressed in the report accurately reflect the personal views of Mr. Ruffalo regarding Vycor Medical and its securities, as of the date of the report. The research report is not an offer or solicitation to buy or sell the securities of Vycor Medical. The report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation.
Contact
Dante F. Ruffalo, JDSenior
Equity Analyst+1.913.579.2071
SOURCE: One Equity Research, LLC